A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia

Study Identifier:

SEP361-122

ClinicalTrials.gov Identifier:

NCT05542264

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Study Details

Medical Condition

Schizophrenia

Study Drug

Drug: SEP-363856
Drug: Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)

Date

Nov 2022 - Feb 2024

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 65 Years

Requirements Information

Protocol Summary

A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters. This study is accepting male and female participants age 18 years to 65 years. This study will be conducted in approximately 6 study sites in the United States. Participation could last up to 13 weeks.

Study Locations

Location

Status

Location

Woodland International Research Group

Little Rock, Arkansas, United States, 72211

Status

N/A

Location

Shari DeSilva

Rogers, Arkansas, United States, 72758

Status

N/A

Location

Midwest Clinical Research Center

Dayton, Ohio, United States, 45417

Status

N/A

Location

Endeavor Clinical Trials

San Antonio, Texas, United States, 78240

Status

N/A